BioCryst Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.22 | -$0.20 | -$0.21 |
| Q2 2024 | 4 | -$0.18 | -$0.16 | -$0.17 |
| Q3 2024 | 3 | -$0.07 | -$0.06 | -$0.07 |
| Q4 2024 | 5 | -$0.14 | -$0.01 | -$0.07 |
| Q1 2025 | 1 | -$0.11 | -$0.10 | -$0.11 |
| Q2 2025 | 1 | -$0.07 | -$0.07 | -$0.07 |
| Q3 2025 | 1 | -$0.04 | -$0.04 | -$0.04 |
| Q4 2025 | 1 | -$0.01 | -$0.00 | -$0.01 |
BioCryst Pharmaceuticals, Inc. Earnings Date And Information
BioCryst Pharmaceuticals, Inc. last posted its earnings results on Monday, November 4th, 2024. The company reported $-0.07 earnings per share for the quarter, missing analysts' consensus estimates of $-0.07 by $0. The company had revenue of 117.09 M for the quarter and had revenue of 331.41 M for the year. BioCryst Pharmaceuticals, Inc. has generated $-1 earnings per share over the last year ($-1.18 diluted earnings per share) and currently has a price-to-earnings ratio of -12.7. BioCryst Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 19th, 2025 based on prior year's report dates.
BioCryst Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/05/2024 | Q3 2024 | -$0.07 | $113.99 M | $117.09 M | ||
| 08/06/2024 | Q2 2024 | -$0.06 | $98.30 M | $109.33 M | ||
| 05/07/2024 | Q1 2024 | -$0.17 | $92.76 M | |||
| 02/27/2024 | Q4 2023 | -$0.31 | $93.40 M | |||
| 11/08/2023 | Q3 2023 | -$0.19 | $86.06 M | $86.74 M | ||
| 08/07/2023 | Q2 2023 | -$0.40 | $81.42 M | $82.49 M | ||
| 05/08/2023 | Q1 2023 | -$0.28 | $68.78 M | |||
| 02/27/2023 | Q4 2022 | -$0.38 | $79.55 M | |||
| 11/04/2022 | Q3 2022 | -$0.23 | $74.78 M | $75.83 M | ||
| 08/05/2022 | Q2 2022 | -$0.32 | $63.33 M | $65.53 M | ||
| 05/09/2022 | Q1 2022 | -$0.40 | $49.92 M | |||
| 02/28/2022 | Q4 2021 | -$0.10 | $47.16 M | |||
| 11/04/2021 | Q3 2021 | -$0.33 | $40.20 M | $40.99 M | ||
| 08/09/2021 | Q2 2021 | -$0.24 | $28.11 M | $49.96 M | ||
| 05/07/2021 | Q1 2021 | -$0.36 | $19.06 M | |||
| 03/01/2021 | Q4 2020 | -$0.34 | $4.02 M | |||
| 11/06/2020 | Q3 2020 | -$0.26 | $3.60 M | $6.10 M | ||
| 08/07/2020 | Q2 2020 | -$0.24 | $2.25 M | $2.87 M | ||
| 05/08/2020 | Q1 2020 | -$0.24 | $4.82 M | |||
| 03/13/2020 | Q4 2019 | -$0.02 | $39.73 M |
BioCryst Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is BioCryst Pharmaceuticals, Inc.'s earnings date?
BioCryst Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 19th, 2025 based off last year's report dates.
-
How can I listen to BioCryst Pharmaceuticals, Inc.'s earnings conference call?
The conference call for BioCryst Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read BioCryst Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for BioCryst Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does BioCryst Pharmaceuticals, Inc. generate each year?
BioCryst Pharmaceuticals, Inc. (:BCRX) has a recorded annual revenue of $331.41 M.
-
How much profit does BioCryst Pharmaceuticals, Inc. generate each year?
BioCryst Pharmaceuticals, Inc. (:BCRX) has a recorded net income of $331.41 M. BioCryst Pharmaceuticals, Inc. has generated $-1.18 earnings per share over the last four quarters.
-
What is BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio?
BioCryst Pharmaceuticals, Inc. (:BCRX) has a price-to-earnings ratio of -12.7 and price/earnings-to-growth ratio is -0.77.
